Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity. Among older AML patients (age >60 years), there are few long-term survivors. Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS) with the 5q-chromosomal abnormality. We report induction of sustained morphologic and cytogenetic complete remission in two older AML patients treated with high-dose, single agent lenalidomide; each patient had trisomy 13 as the sole cytogenetic abnormality.
Introduction
Advances in the treatment of AML, including cytogenetic and molecular riskstratification, have improved clinical outcomes for younger patients (age < 60 years) [1] [2] [3] . In contrast, older AML patients given standard cytotoxic treatments have a dismal prognosis with a median survival of less than one year 4, 5 . Poor outcomes in older patients, who constitute the bulk of AML cases, are related to the combination of unfavorable leukemia biology and co-morbidities that limit treatment options 5, 6 . Thus, successful development of novel AML therapy requires not only improved understanding of leukemogenesis but also tolerability of the drug in older patients.
Novel drug development strategies are assisted by identification of molecular markers or biologic features of disease associated with increased likelihood of clinical response to the treatment.
Lenalidomide is active against a number of hematologic malignancies and FDA approved for both relapsed multiple myeloma and low risk MDS with the 5q-cytogenetic abnormality. Cytogenetic responses observed in previous clinical trials of lenalidomide in MDS suggest that lenalidomide eliminated the abnormal MDS clone [7] [8] [9] . The lenalidomide dose in these trials was limited to 10 mg/day by drug-related myelosuppression; this dose results in substantially lower plasma concentrations compared with higher dosing strategies 10, 11 . Since therapy-related myelosuppression is routine in AML treatment and may be necessary to obtain complete remissions, we explored the activity of higher doses of lenalidomide in AML in two independent clinical trials. We report here sustained morphologic and cytogenetic complete remissions 
Case Reports
At both institutions involved, protocols were approved by scientific review committees and then at local Institutional Review Boards and informed consent was obtained in accordance with the Declaration of Helsinki.
Case 1.
A 71 year old male with no prior history of MDS presented with dyspnea and pancytopenia. Bone marrow (BM) biopsy showed 90% myeloblasts, undifferentiated (FAB M0) AML ( Fig 1A) ; flow cytometry revealed that the blasts expressed CD34, CD33, CD13, and CD117. Metaphase cytogenetics showed trisomy 13 in 5/20 metaphase cells but no other abnormalities (Fig 1B) . FISH studies excluded abnormalities of chromosomes 5, 7, 8, and 11q23. Patient characteristics are summarized in Table 1 .
After providing informed consent, the patient was treated on a human research protection office (HRPO)-approved clinical trial evaluating lenalidomide in untreated AML for patients aged > 60 years at Washington University in St. Louis, MO (clinicaltrials.gov: NCT00546897). Study therapy consisted of high-dose lenalidomide at 50 mg/day x 14 days, followed by 30 days off therapy, and then a second course of 50 mg/day x 21 days. Peripheral blood AML blasts cleared after the initial 14 day course of lenalidomide. At day 30, the BM biopsy showed 25% cellularity with 72% blasts (and was FLT3-ITD positive). Following cycle 2 of high-dose lenalidomide, BM biopsy showed aplasia with <10% cellularity, though blasts were present, and he remained transfusion dependent. Cycle 2 was complicated by two episodes of neutropenic fever requiring hospitalization, for which he received G-CSF. Thirty days after completing the 2 high-dose cycles, he began low-dose lenalidomide (10 mg daily in 4 week cycles), as per the clinical protocol. After 21 days of low-dose lenalidomide, his blood cell counts normalized without transfusion or growth factors. At the completion of his first low-dose cycle (124 days from initiation of lenalidomide) BM showed 60% cellularity with < 5% blasts. Cytogenetics showed no clonal abnormalities, and FLT3-ITD was negative. This CRc was confirmed on two subsequent BM biopsies at 6 and 16 weeks following the initial CRc. The patient continued on low dose lenalidomide for 10 months, but subsequently relapsed (duration of CRc was 9 months).
Notably, 0/13 non-trisomy 13 abnormality AML patients treated on the Washington University clinical trial achieved CR, although two PRs were observed.
There was one additional patient with trisomy 13 on the study, though the patient also had additional cytogenetic abnormalities as 48,XY+der(1)t(1;1)(p11;q25),+13. This patient received only 6 days of lenalidomide before going off study due to infection.
Case 2.
A 68 year old male presented with marked pancytopenia and was found to have relapsed AML. Approximately 3.5 years prior, he was diagnosed with AML arising from MDS; at that time, he had normal karyotype. Due to medical comorbidities including ischemic cardiomyopathy, at the original presentation he received induction with fludarabine, cytarabine, and G-CSF (FLAG), and achieved CR1. He then received one cycle of cytarabine (1.5gm/m2 x 6 doses) consolidation, completing all therapy 3 years prior to the current relapse. At relapse, BM biopsy showed 40% myeloblasts, FAB M2 AML(see Table 1 
Discussion
We report induction of sustained CRc in two older AML patients with trisomy 13 treated with single agent lenalidomide. In AML, cytogenetic abnormalities remain the most important disease-related prognostic factor [12] [13] [14] [15] . Occurring in about 3% of AML cases, AML with trisomy 13 is rare, and it is associated with a very poor prognosis 13, 16 .
Each of the two patients achieved morphologic and cytogenetic CR after a prolonged delay (78 and 124 days, respectively) from initiation of intermittent, high-dose lenalidomide. No other anti-leukemic agent was administered; the remissions were a direct result of lenalidomide therapy. To our knowledge, this is the first report of highdose lenalidomide inducing morphologic and cytogenetic CRs in AML or any other myeloid disorder with trisomy 13 as the sole chromosomal abnormality.
The biologic mechanism of lenalidomide clinical activity in hematologic malignancies remains unclear. Clinical and cytogenetic responses to lenalidomide in MDS patients have been strongly associated with the 5q-chromosomal abnormality [7] [8] [9] , providing a genetic starting point for studies to define lenalidomide's mechanism of action in this disease. Indeed, potential genes of interest in 5q-MDS have been identified including SPARC 17 and RPS14
suggesting potential targets that may be relevant to the lenalidomide activity observed in this report. Further analysis of lenalidomide activity in additional trisomy 13 AML patients may ultimately lead to better understanding of myeloid leukemogenesis and aid in the development of new targeted therapeutic approaches for AML.
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